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Background: Pancreatic adenocarcinoma is one of the most dreaded cancers with very low survival rate and poor
prognosis to the existing frontline chemotherapeutic drugs. Gene therapy in combination with a cytotoxic agent
could be a promising approach to circumvent the limitations of previously attempted therapeutic interventions.
Method: We have developed a redox-responsive thiolated gelatin based nanoparticle system that efficiently
delivers its payload in the presence of glutathione-mediated reducing intra-cellular environment and could be
successfully used for site-specific wt-p53 expressing plasmid DNA as well as gemcitabine delivery by targeting
epidermal growth factor receptor (EGFR). Efficacy studies were performed in subcutaneous human adenocarcinoma
bearing SCID beige mice along with molecular level p53 plasmid and apoptotic marker expression by PCR and
western blot for all study groups.
Results: Efficacy studies demonstrate an improved in vivo targeting efficiency resulting in increased transfection
efficiency and tumor growth suppression. In all the treatment groups, the targeted nanoparticles showed better
anti-tumor activity than their non-targeted as well as non-encapsulated, naked therapeutic agent counterparts
(50.1, 61.7 and 77.3% tumor regression by p53 plasmid alone, gemcitabine alone and in combination respectively).
Molecular analysis revealed a higher mRNA expression of transfected p53 gene, its corresponding protein and that
the tumor cell death in all treatment groups was due to the induction of apoptotic pathways.
Conclusions: Gene/drug combination treatment significantly improves the therapeutic performance of the delivery
system compared to the gene or drug alone treated groups. Anti-tumor activity of the thiolated gelatin loaded
wt-p53 plasmid or gemcitabine-based therapy was attributed to their ability to induce cell apoptosis, which was
confirmed by a marked increase in mRNA level of proapoptotic transcription factors, as well as, protein apoptotic
biomarker expression and significant decrease in the anti-apoptotic transcription factors.
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Pancreatic cancer is the fourth leading cause of cancer-
related deaths with an estimated 45,220 newly diagnosed
cases and an expected death of 38,460 patients in 2013
in United States alone [1]. Only 10% of the diagnosed
patients have a resectable stage of tumor that could be
potentially cured by surgical procedures [2]. Even in the* Correspondence: m.amiji@neu.edu
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unless otherwise stated.case of surgically resectable tumor, incidence of aggres-
sive metastasis resurgence often leads to development of
resistance to conventional chemo and radiation therapy.
Despite several advancements in diagnosis, surgical
methods, chemo and radiation therapy, the prognosis of
the disease remains poor with less than 5% five-year sur-
vival rate. Poor prognosis can be largely attributed to
late diagnosis of the disease where most of the patients
present with advanced stages localized or metastatic
cancer growth. Patients with advanced stage localizedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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while those suffering from a metastatic form of the dis-
ease only have a 3–6 months median survival [3].
Chemotherapy still remains the most popular ap-
proach for treatment of advanced stage localized or
metastatic pancreatic adenocarcinoma and gemcitabine
(2′-2′-difluorodeoxycytidine) has been used as the front-
line therapeutic drug for this purpose. However, gemci-
tabine in combination with other therapeutic agents
such as platinum analogues [4,5], anti-metabolites [6-8]
or topoisomerase inhibitors [9,10], has failed to elucidate
any improvement in the therapeutic outcome or survival
rate. FLOFIRINOX recently has been proposed as an
alternative to gemcitabine-based therapy due to an im-
proved median overall survival of 11.1 months compared
to 6.8 months [11]. However, there still lacks an overall
consensus on the optimal therapeutic regimen for pan-
creatic cancer where the majority of the chemotherapeu-
tic clinical trials have been terminated in their phase II
or III stage due to unfavorable or insignificant outcomes.
A recent review on analysis of clinical trials on second-
line treatment in locally advanced or metastatic pancre-
atic cancer also summarizes that neither FLOFIRINOX
nor gemcitabine-based regimen have been able to pro-
vide a standard of care against the disease [12]. There is,
therefore, an urgent need to revisit the therapeutic ap-
proach and design novel strategies to overcome this
disease.
Every case of pancreatic cancer can be characterized
by nearly 63 genetic mutations that could be classified
into 12 core signaling pathways [13], providing diversity
in physico-chemical signature of a tumor. Mutation in
p53 tumor suppressor gene is a well-established fact as-
sociated with pancreatic cancer [14], which not only re-
sults in promotion of tumorigenesis but also affects the
apoptotic mechanism of tumor cell death and is further
associated with induction of chemo-resistance [15,16].
Gemcitabine or 5-fluorouracil resistance in pancreatic
cancer has been attributed to an altered expression of
apoptosis-regulating genes of the Bcl-2 family [17],
which are regulated by p53 level in the cell. In vitro evi-
dence clearly suggests that introduction of wild-type p53
gene into the pancreatic cancer cells increases their sen-
sitivity to gemcitabine therapy [18]. Gene delivery, how-
ever, is extremely challenging due to instability of
genetic material and lack of targeting and is often
achieved with the aid of a suitable delivery system. Also,
another mechanism for gemcitabine resistance in pan-
creatic cancer cells is due to lower intracellular drug up-
take attributed to lack of nucleoside transporter [19],
which warrants for alternative delivery methods. Com-
bination therapy of p53 gene along with gemcitabine en-
capsulated in a delivery vehicle therefore would be a
promising approach to augment therapeutic benefits andovercome challenges associated with pancreatic cancer
treatment.
We have previously reported long-circulating redox-
responsive thiolated type B gelatin (SH-Gel-PEG) that
shows tremendous potential as stimuli-responsive gene
delivery vehicle [20-26], such that the thiol crosslinks of
the nanoparticles could be disrupted in the glutathione-
mediated reducing intracellular environment of the cell
resulting in payload release and transgene expression.
We recently developed an EGFR-targeted thiolated
gelatin-based delivery system that could deliver wild-
type p53 (wt-p53) gene efficiently in Panc-1 human
adenocarcinoma cells. EGFR-targeted thiolated gelatin
nanoparticles loaded with wt-p53 plasmid showed rapid
uptake and plasmid release, enhanced gene expression
and subsequent higher protein levels causing apoptosis
induction and cell death [26]. Qualitative and quantita-
tive biodistribution studies in Panc-1 tumor bearing
mice showed a significantly higher tumor accumulation
of the targeted long circulating thiolated gelatin nano-
particles (SH-Gel-PEG-peptide) compared to SH-Gel-
PEG and SH-Gel nanoparticles [27].
In the present work, we have not only evaluated the
in vivo transfection efficiency and therapeutic efficacy of
different gelatin nanoparticles, but also show that these
nanoparticles could be used for delivery of gemcitabine
in vitro and in vivo, thus allowing the possible combin-
ation of gene and drug therapy against pancreatic can-
cer. Subcutaneous animal models are most commonly
used tumor models in preclinical research since they are
fast to develop, easy to characterize and present reason-
able heterogeneity and complexity of the actual human
tumors [28]. Subcutaneous pancreatic adenocarcinoma
model was therefore developed in severe combined im-
munodeficient (SCID) beige mice using Panc-1 cells for
all the in vivo studies.
Methods
Preparation of wt-p53 plasmid loaded gelatin
nanoparticles
Thiolated gelatin was synthesized and purified using an
established method that conjugates 2-iminothiolane to
primary amine groups on type B gelatin [23,25]. Lyophi-
lized purified thiolated gelatin was used for nanoparticle
preparation and encapsulation of plasmid by desolvation
method developed and optimized in our lab [23,25,29].
Typically, 1% (w/v) thiolated gelatin solution was pre-
pared in deionized distilled water at 37°C and pH was
adjusted to 7 using 0.2 M NaOH. 1 mg plasmid DNA
was gently mixed in the gelatin solution followed by
slow addition of chilled ethanol with continuous stirring
at 600 rpm. Gelatin nanoparticles are formed when the
solvent composition changes to 75% hydro-alcoholic so-
lution following which 0.5 mL 8% (v/v) glyoxal solution
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particles were purified and concentrated by tangential
flow filtration, freeze-dried and stored at 4°C until used.
SH-Gel-PEG and SH-Gel-PEG-peptide nanoparticles
were prepared by a method described before [23,29].
Briefly, freeze-dried nanoparticles (10 mg/mL) were sus-
pended in 0.1 M phosphate buffer (pH 7.4) and incu-
bated with methoxy-PEG-succinimidylcarbosyl methyl
ester (mPEG-PEG-SCM, MW 2000 Da) or maleimide-
PEG-SCM (MAL-PEG-SCM, MW 2000 Da) for 2 h at
room temperature with slow stirring to form SH-Gel-
PEG and SH-Gel-PEG-MAL particles respectively. The
particles were purified by ultra-centrifugation at
18,800 g for 30 min (Beckman Coulter Optima™ LE-
80 k; rotor 70Ti; Brea, CA), washed twice in deionized
water and freeze-dried. SH-Gel-PEG-MAL particles
(10 mg/mL) were suspended in 0.1 M phosphate buffer
(pH 6.5) with 10% weight of 12 amino acid EGFR bind-
ing peptide flanked with four glycine spacer and a ter-
minal cysteine (i.e., Y-H-W-Y-G-Y-T-P-Q-N-V-I-G-G-G-
G-C) for 6 h at room temperature to facilitate binding of
the sulfhydryl group of cysteine to maleimide group on
PEG. The peptide modified nanoparticles were purified
by ultra-centrifugation at 16,000 rpm for 30 minutes,
washed twice in deionized water, freeze-dried and stored
at 4°C until used. The physico-chemical properties, plas-
mid loading efficiency and stability of the particles were
characterized, details of which have been published else-
where [26]. The typical average size of gelatin nanoparti-
cles was found to be between 130-230 nm with SH-Gel
being the smallest in size (~ 130 nm). PEG modification
of the SH-Gel particles increased the size to nearly 180 nm
and subsequent peptide functionalization further increased
the size to nearly 230 nm. The average surface charge of
the nanoparticles was found to be around -20 mV and
the p53 gene loading efficiency was found to be around
95%.
Preparation of gemcitabine loaded gelatin nanoparticles
10 mg base form of gemcitabine was dissolved in 5 mL
methanol with 100 mg succinimidyl 3-[2-pyridyldithio]-
propionate) (SPDP) at 80°C under reflux for 48 hours.
The reaction was monitored by thin-layer chromatog-
raphy (TLC) (Rf 0.67 (CHCl3/MeOH, 8:2)). Solvent was
removed in vacuo with rotary evaporator IKA RV10 at
60°C, and the residue was purified by silica gel chroma-
tography (200 mL, CHCl3 and 200 mL CHCl3/MeOH,
9:1) to give gemcitabine-SPDP. UV spectrometer was
used to monitor elute at λ = 268 nm.
Purified gemcitabine-SPDP was dried in vacuo and
then dissolved in 1 mL dimethyl sulfoxide (DMSO). For
conjugation with gemcitabine-SPDP, thiolated gelatin
(10 mg/mL) was dissolved in 0.1 M PBS/EDTA (100 mM
sodium phosphate, 150 mM NaCl, 1 mM EDTA, 0.02%sodium azide, pH 7.5). Gemcitabine-SPDP was added to
thiolated gelatin solution and stirred overnight at room
temperature. Formed gemcitabine-gelatin disulfide con-
jugates were dialyzed against DI water overnight and
then purified polymers were used for nanoparticle
synthesis. The conjugation of gemcitabine-SPDP and
gemcitabine-gelatin were confirmed by reverse phase
HPLC, using a C18 column (Thermo-Fisher Scientific,
MA), with the UV detector set at 268 nm. The mobile
phase was composed of 20% of MeOH/H2O (5:5) and
80% 0.5 M ammonium acetate solution. The elution was
performed by isocratic flow and flow rate was 1 mL/min.
Standard curve was established with pure gemcitabine
and release of drug was determined based on standard
curve. Gemcitabine loaded gelatin nanoparticles were
synthesized following the protocol similar to one used for
p53 gene loaded nanoparticle synthesis (described above).
The size and charge measurement of gemcitabine loaded
SH-Gel, SH-Gel-PEG and SH-Gel-PEG-peptide nanopar-
ticles were found to be consistent with that observed for
p53 gene loaded nanoparticles. The average particle size
was found to be between 130-230 nm and the average
surface charge for all the different nanoparticle systems
was found to be around -20 mV.
In vitro release of gemcitabine from the nanoparticles
was performed in the presence of proteolytic enzyme
(0.2 mg/mL) and glutathione to mimic the intracellular
(5 mM) and extracellular (0.1 mM) environment in the
tumor [30]. The drug release studies were carried out at
37°C with PBS solution as control. 20 mg of gemcitabine-
loaded nanoparticles were weighed into microcentrifuge
tubes and dissolved in 1.5 ml of buffer containing gluta-
thione and/or protease. Samples were incubated in
temperature controlled shaker and 0.5 ml of supernatant
was drained at specified intervals (15, 30, 45, 60, 120, 240
and 360 minutes). Sink conditions were maintained by re-
placing an equal volume of release medium each time.
Collected samples were centrifuged at 13,000 rpm for
15 min, filtered through 0.2 μm filters and analyzed by re-
verse phase HPLC, using a C18 column using assay condi-
tion described above. Additional file 1: Figure S1 shows
the drug release profile of SH-Gel, SH-Gel-PEG and SH-
Gel-PEG-peptide nanoparticles.
Subcutaneous pancreatic tumor model development
Panc-1 human pancreatic adenocarcinoma cells were ob-
tained from American Type Culture Collection ATCC,
Manassas, VA) (Manassas, VA) and were grown in DMEM
media supplemented with 10% FBS and 1% Pen-Strep.
Animal handling and procedures were performed accord-
ing to an approved protocol by Northeastern University,
Institutional Animal Care and Use Committee (NU-
IACUC) and the Radiation Safety Committee within the
office of Environmental Health and Safety. Six weeks old
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were purchased from Charles River Laboratories (Wil-
mington, MA) and were used for efficacy studies.
To inoculate subcutaneous tumors, animals were
mildly anesthetized by inhalation of 2% Isoflurane (St.
Joseph, MO) in 100% oxygen and approximately 3 mil-
lion Panc-1 cells in 100 μl of PBS and Matrigel mixture
(1:1) was injected subcutaneously into the left flanks of
female SCID Beige mice. Tumors were allowed to grow
and reach a palpable volume and during this period, the
animals were monitored for food/water intake, body
weight and any signs of discomfort. Any animals that
seemed lethargic were sacrificed.
In vivo nanoparticle administration and dosing schedule
The animals were randomized into different treatment
groups for efficacy studies when the tumor volume
reached 200 mm3. The dosing schedule and treatment
groups for different formulations of wt-p53 alone, gemci-
tabine alone and wt-p53/gemcitabine in combination have
been outlined in Additional file 1: Figure S2. The plasmid
treatment group mice were each administered with 20 μg
plasmid at day 0, 2 and 4. From the 12 mice per treatment
group, 3 mice were euthanized at day 7 and 18 for in vivo
transfection analysis while remaining 6 mice were sacri-
ficed after completion of the study (day 33). Similarly,
mice receiving gemcitabine treatment were intravenously
administered with 4 doses of free or formulated drug at a
dose of 5 mg/kg at day 0, 7, 14 and 21.
The wt-p53 plasmid and gemcitabine combination effi-
cacy study was performed where plasmid loaded particles
were dosed at day 0, 2 and 4 followed by gemcitabine
loaded particle administration at day 5, 12, 19 and 26. In
vitro studies of gelatin nanoparticle loaded p53 gene trans-
fection followed by assessment of its expression and effect
on downstream apoptosis markers revealed that apoptotic
activity is maximum 96 hour post-transfection [26]. The
first dose of gemcitabine was therefore administered at
day 5 when the apoptotic effect of p53 gene would have
taken effect. All doses for efficacy studies were adminis-
tered to the animals intravenously via tail vein injection.
Tumor volumes were measured and recorded every 3 days
for all treatment groups and all the mice were sacrificed at
the completion of the study (day 33). The mice were sacri-
ficed by isoflurane inhalation followed by cervical disloca-
tion, tumor mass was weighed and flash frozen in liquid
nitrogen for analysis of protein, mRNA and apoptotic
markers.Quantitative transfection efficiency and downstream
apoptosis marker evaluation
In vivo gene transfection efficiency was evaluated by quan-
titative polymerase chain reaction (qPCR). For mRNAextraction, tumors were excised and stored in RNAlater®
(Invitrogen, Carlsbad, CA) at 4°C overnight and then
-20°C for long-term storage. mRNA of tumor samples was
extracted using Powergen 125 tissue homogenizer (Fisher
Scientific, Waltham, MA) and TRIzol® Reagents, Pure-
Link® RNA Mini Kit (Invitrogen, Carlsbad, CA). Extracted
RNA was measured with Nano-Drop® 2000 (Thermo-
Scientific, Wilmington, DE). cDNA was synthesized from
2 μg of extracted mRNA with SuperScript® III First-Strand
Synthesis SuperMix Kit (Invitrogen, Carlsbad, CA). 2 μL
of synthesized cDNA and LightCycler® 480 SYBR Green
kit (Roche, Indianapolis, IN) were used for qPCR in Light-
Cycler® 480 and analyzing mRNA levels of Flag-p53 and
corresponding downstream transcription factors. Primer
sequences (Additional file 1: Table S1) for p53, Bax, Bcl-2,
β-actin, DR5, Apaf-1, PUMA, caspase 3 and caspase 9
were synthesized in Eurofins MWG Operon (Huntsville,
AL). All the results for gene expression have been calcu-
lated and reported relative to the control group.Qualitative transfection efficiency and downstream
apoptosis marker evaluation
Proteins were extracted from tumors using Total Protein
Extraction Kit (Millipore, Billerica, MA) and Powergen
125 tissue homogenizer (Fisher Scientific, Waltham,
MA). Tissue lysate samples were analyzed for total pro-
tein concentration using BCA assay (Pierce, Rockford,
IL, USA). 50 μg of total protein extract was run on pre-
cast 4-20% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) system at 200 V for 30 mi-
nutes. Subsequently, protein bands on gel were trans-
ferred onto PVDF membrane by iBlot® Dry Blotting
System (Invitrogen, Carlsbad, CA). Membrane was
blocked with 5% milk in Tween®-containing Tris buffer
saline (TBS-t) for 1 hour at room temperature. Mem-
brane was cut and incubated with 1:1,000 dilution of pri-
mary rabbit β-actin antibody, 1:500 primary rabbit
cleaved PARP antibody, 1:500 primary rabbit cleaved
caspase 3 (Cell Signaling Technology Inc., Danvers, MA)
or 1:1000 dilution of primary mouse monoclonal anti-
FLAG®M2 antibody (Sigma-Aldrich, St. Louis, MO) sep-
arately overnight at 4°C. Membranes were then washed
three times with TBS-t and incubated with 1:2,000 dilu-
tions of secondary anti-rabbit or anti mouse horse-
radish peroxidase-conjugated IgG(Cell Signaling Tech-
nology Inc., Danvers, MA) in TBS-t for 1 hour at room
temperature. After rinsing excess antibody with TBS-t
and water, 4 ml ECL substrate (Pierce, Rockford, IL,
USA) was added and mixed with membranes for 5 mi-
nutes, which is cleaved by peroxidase to give a chemilu-
minescent product. The membranes were visualized
using Kodak Digital X-ray Specimen (DXS) System. β-
actin was used as protein loading control.
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labeling (TUNEL) analysis
TUNEL analysis was performed on the tumor sections to
confirm the DNA fragmentation as a result of activation
of apoptotic signaling cascade. Excised tumors were em-
bedded in frozen section medium (Richard-Allan Neg 50,
Thermo Scientific, Waltham, MA), flash frozen in liquid
nitrogen, and stored at -80°C until use. Embedded tumors
were thawed to -20°C, cryo-sectioned into 10 μm thick
sections using the Microm® HM550 cryostat (MICROM
International GmbH, Germany), and mounted onto glass
slides (SuperFrost Plus®, Thermo Scientific, Waltham,
MA). Sections were air dried at room temperature and
then stored at -20°C. DeadEnd™ Fluorometric TUNEL
System (Promega, Madison, WI) was used for tissue
staining. After staining, tissues were mounted with
Fluoromount-G (Southern Biotech, AL), covered with a
coverslip, sealed with nail polish and imaged by Olympus
BX61 microscope.Statistical analysis
All the statistical analysis was performed using Prism 5.0
software (Graph Pad Software Inc., San Diego, CA).
Results were expressed as mean ± SD of the at least three
independent experiments. Data was analyzed by Student’s
t-test or one way ANOVA followed by Bonferroni’s post
hoc analysis for multiple comparisons. Differences were
considered statistically significant at p < 0.05.Results
In vitro studies show enhanced activity and targeting
efficiency
The wt-p53 loaded thiolated gelatin nanoparticles were
in the size range of 150-250 nm as confirmed by light
scattering and scanning electron microscopy analyses. In
vitro studies show high transfection efficiency and subse-
quent increased production of p53 protein in Panc-1
cells that results in triggering of downstream apoptotic
pathways, inducing cell death [26]. We simultaneously
synthesized gemcitabine conjugated to gelatin according
to the scheme shown in Additional file 1: Figure S3,
which resulted in particles in the size range of 150-
250 nm with a negative surface charge similar to the
values obtained for wt-p53 plasmid-loaded nanoparticles.
HPLC analysis reveals 24.9% gemcitabine loading effi-
ciency in the particles, which could be released by treat-
ment with 0.2 mg/mL protease and 5 mM DTT
treatment, emulating the cancer intracellular environ-
ment [31]. In vitro cytotoxicity assessment in Panc-1 cells
show IC50 values for free drug, Gem-SPDP, Gem-Gel,
Gem-Gel-PEG and Gem-Gel-PEG-peptide nanoparticles
to be 129.9 ± 23.87, 8.39 ± 1.79, 24.76 ±7.99, 20.08 ± 6.97
and 17.08 ± 2.32 μM respectively, confirming that thedrug-loaded gelatin nanoparticles shows improved cyto-
toxicity compared to the free drug.
Gelatin particles loaded with wt-p53 gene show efficient
transfection ability and anti-tumor activity in vivo
Subcutaneous human pancreatic adenocarcinoma (Panc-
1) bearing female SCID beige mice (n = 12) were intraven-
ously dosed with wt-p53 naked and gelatin encapsulated
plasmid (20 μg/dose) at day 0, 2 and 4 and tumor volume
was monitored as a function of time till the end of the
study (day 33). Also, 3 mice from each treatment group
were sacrificed at day 7 and 18 to measure tumor weight,
gene expression and analysis of downstream apoptotic
markers. Plasmid loaded SH-Gel-PEG-peptide and SH-
Gel-PEG nanoparticles produced tumor growth inhibition
of 50.1% (p < 0.01) and 38.3% (p < 0.05) respectively com-
pared to control group, confirming that wt-p53 gene ad-
ministration show tumor growth suppression (Figure 1a).
On the contrary, naked as well as SH-Gel loaded plasmid
shows little anti-tumor activity suggesting that targeting
and long-circulating characteristics are essential for en-
hanced intra-tumor localization of the nanoparticles.
Weight of the tumors obtained from mice of different
treated groups after day 7, 18 and 33 (Figure 1b) do not
show remarkable difference at day 7 and 18 but were
found to be significantly decreased compared to control at
day 33.
The expression of wt-p53 and downstream apoptotic
markers in the tumors after day 7, 18 and 33 were con-
firmed quantitatively by qPCR (Figure 2a-d) and qualita-
tively by western blot analysis (Figure 2e). SH-Gel-PEG-
peptide treated tumors show remarkably higher levels of
p53 mRNA (p < 0.001) as well as protein after 7 and
18 days of treatment while SH-Gel-PEG treated tumors
also show higher p53 mRNA expression compared to
control. Naked plasmid on the other hand did not show
any change in mRNA level, confirming that a delivery
system is essential for successful transfection and gene
activity in vivo. Further, no significant p53 mRNA or
protein expression was observed in any of the treatment
groups (Figure 2a,e).
Expression of p53 gene has been long known to induce
stable growth arrest and apoptosis in cancer cells [15,16]
and it is therefore pertinent to assess the mRNA and
protein levels of downstream apoptotic markers to valid-
ate the activity of p53 protein. To assess the effect of
exogenous wt-p53 on apoptotic pathway, downstream
pro-apoptotic transcription factors Bax, DR5, Apaf-1,
PUMA, caspase3 and caspase9 and anti-apoptotic Bcl-2
were also analyzed with qPCR (Figure 2B-D). The results
clearly indicate a marked increase in all the pro-
apoptotic transcription factors upon treatment with SH-
Gel-PEG-peptide while SH-Gel-PEG and SH-Gel treated
tumors show a moderate increase in expression. These
Figure 1 In vivo anti-tumor activity of wt-p53 loaded gelatin nanoparticles. (a) Volume change as a function of time showing 27.9, 38.3*
and 50.1%** reduction in tumor growth on day 33 for wt-p53 loaded SH-Gel, SH-Gel-PEG and SH-Gel-PEG-peptide nanoparticle treated tumor
respectively. (b) Tumor weights on day 7, 18 and 33. Results are presented as mean ± SD (n = 3 for day 7 and 18; n = 6 for day 33) (* p < 0.05;
** p < 0.01; *** p < 0.001).
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cleaved caspase 3 and cleaved PARP in tumors, signature
protein indicators confirming induction of apoptosis
(Figure 2e). Both proteins levels were increased with
transfection of wt-p53, where highest protein levels were
observed with SH-Gel-PEG-peptide p53 treatment on
day 18. These studies demonstrated that expression of
wild-type p53 triggered apoptotic pathway in tumors
through up-regulation of pro-apoptotic transfection fac-
tors and down-regulation of anti-apoptotic transfection
factors. TUNEL stained imaging of tumors xenografts
was also performed for visual analysis of distribution of
apoptotic cells. Images show that SH-Gel-PEG-peptide
treated tumors have the highest number of TUNEL posi-
tive cells (Figure 2f ). SH-Gel PEG p53 and SH-Gel NP
p53 were also able to increase the apoptotic cell popula-
tion compared to saline and naked plasmid control.
Gemcitabine conjugated gelatin nanoparticles show
increased cytotoxicity and tumor growth inhibition
Prior studies for pancreatic cancer treatment involving
gene therapy in combination with gemcitabine have ad-
ministered drug dose as high as 100 mg/kg/week [32]
but improved efficacy due to intervention of nano-
delivery systems has significantly reduced the required
dose [33-35]. In this study, we administered 4 weekly
doses of 5 mg/kg to the subcutaneous human pancreatic
adenocarcinoma (Panc-1) bearing female SCID beige
mice followed by tumor volume measurement every
3 days till day 33. Gem-Gel-PEG-peptide treatment
group inflicted maximum tumor growth inhibition
(61.7%, p < 0.001) while Gem-Gel-PEG and Gem-Gel
treatment groups caused 50.7 (p < 0.01) and 39.4% (p <
0.05) growth inhibition (Figure 3a). Interestingly, gemci-
tabine drug in solution did not show any statistically sig-
nificant tumor inhibition effect, emphasizing the
improved efficacy of the drug by virtue of the delivery
vehicle. Tumor weight measured at the completion ofthe efficacy study (day 33) corroborated the trend indi-
cated by tumor volume measurement where EGFR-
targeted nanoparticle treated tumor shows minimum
mass (p < 0.001) compared to non-targeted and non-
PEG gelatin nanoparticle treated tumors (Figure 3b).
The mechanism for gemcitabine action is based on
DNA damage that triggers the apoptotic pathway. Effect
of gemcitabine treatment on apoptosis was evaluated
quantitatively by measurement of mRNA levels of tran-
scription factors (Bax, Bcl-2, DR5, Apaf-1, PUMA, cas-
pase 3 and caspase 9) by qPCR and qualitatively by
protein analysis. Targeted nanoparticles significantly in-
creased mRNA expression of all the pro-apoptotic tran-
scription factors (p < 0.001) while Gem-Gel-PEG and
Gem-Gel nanoparticles were also able to increase the ex-
pression of these transcription factors, but to lesser ex-
tent (Figure 4a). Besides, anti-apoptotic transfection
factor Bcl-2 mRNA level was slightly decreased with
nanoparticle treatments. Protein analysis by western blot
validated these results, where both cleaved caspase 3 and
cleaved PARP show a moderate increase with nanoparti-
cles treatment (Figure 4b) where the highest protein
level was observed in Gem-Gel-PEG-peptide treated tu-
mors. Gemcitabine induced DNA damage was also
assessed by TUNEL staining, which showed maximum
TUNEL-positive cells in targeted nanoparticle treatment
group compared to non-targeted and non-PEG nanopar-
ticle treatment (Figure 4c). These studies demonstrated
that active targeted delivery of gemcitabine into tumors
showed enhanced anti-tumor activity by successfully
triggering the apoptotic pathway.
Combination wt-p53/gemcitabine treatment shows
remarkable inhibition in tumor growth
We studied the efficacy of wt-p53 and gemcitabine com-
bination treatment in subcutaneous human pancreatic
adenocarcinoma bearing female SCID beige mice. The
tumor bearing animals (n = 6) first received 3 doses of
Figure 2 (See legend on next page.)
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Figure 2 Transfection efficiency and apoptotic activity of wt-p53 loaded gelatin nanoparticles. (a) p53 mRNA expression in tumors.
Results are presented as mean ± SD (n = 3 for day 7 and 18; n = 6 for day 33). mRNA expression level for downstream apoptotic markers after
(b) day 7, (c) day 18 and (d) day 33. (n = 3 for day 7 and 18; n = 6 for day 33) (*p < 0.05; **p < 0.01; ***p < 0.001). (e) Western blot analysis for p53,
cleaved PARP, cleaved caspase 3 and β-actin protein expression in treated tumors. (f) TUNEL analysis of apoptotic activity in the wt-p53 treated
tumors. Sections of tumor tissues imaged after treatment for 7, 18 and 33 days for TUNEL positive (brown) cells. All images were acquired at
20× with scale bar of 50 μm.
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thiolated, non-targeted and EGFR-targeted thiolated gel-
atin nanoparticles at day 0, 2 and 4. Gemcitabine conju-
gated to gelatin was administered in 4 weekly doses
(5 mg/kg) at day 5, 12, 19 and 24. Tumor volume meas-
urement during the course of the study showed maximum
tumor growth inhibition by targeted nanoparticle based
combination treatment (77.3%, p < 0.001) while non-
targeted and non-PEG modified systems showed 63.3 and
57.6% (p < 0.001) growth inhibition (Figure 5a) compared
to control. Importantly, combination treatment by tar-
geted system proved to be most effective in tumor growth
inhibition compared to individual wt-p53 gene (Figure 1a)
or gemcitabine (Figure 4a) treatment using same delivery
system (50.1 and 61.7% respectively).
The increased tumor growth inhibition suggests a syn-
ergistic contribution of the two therapeutic moieties in
the combination treatment. A recent report also suggests
that p53 gene transfection in pancreatic cancer sensitizes
the cells to gemcitabine therapy, which could be an al-
ternative mechanism involved in improving the thera-
peutic outcome [36]. However, since p53 gene alone
shows significant tumor growth suppression in the ab-
sence of gemcitabine, the possibility of a synergistic ef-
fect seems more likely. Tumor weight measurements
performed at the end of the study (day 33) also showed
a significant decrease in tumor mass of treated group
compared to the control, further confirming that gene-
drug combination treatment results in tumor growth in-
hibition (Figure 5b). The tumors obtained from miceFigure 3 In vivo anti-tumor activity of gemcitabine conjugated gelati
39.4*, 50.7** and 61.7%*** reduction in tumor growth on day 33 for Gem-G
respectively. (b) Tumor weights were measured at day 33. Results are presetreated with EGFR-targeted system show minimum
mass, which was consistent with the trend obtained
from tumor volume measurements.
Wt-p53 mRNA expression levels were checked for the
treatment groups quantitatively by qPCR, which show
higher expression in tumors treated with targeted nano-
particles but the expression level in general was low for
all treatment groups (Figure 6a). Similar expression pro-
file was also observed in tumors harvested after day 33
from mice treated with wt-p53 encapsulated in gelatin
nanoparticles (Figure 2a), suggesting loss of plasmid ac-
tivity over time. Western blot analysis for p53 protein in
tumor treated with combination therapy did not show
detectable signal, further implying the low mRNA and
subsequent protein level. Analysis of mRNA levels of the
transcription factors for downstream apoptosis pathway
reveals that all the pro-apoptotic markers are up re-
gulated in tumors treated with combination therapy
using targeted gelatin nanoparticles while anti-apoptotic
marker Bcl-2 is largely down regulated (55%) (Figure 6a).
SH-Gel and SH-Gel-PEG nanoparticle treated tumors,
on the other hand, show a moderate increase in the pro-
apoptotic markers compared to the control. Western
blot analysis of cleaved caspase 3 and cleaved PARP as
downstream apoptotic proteins was performed on sam-
ples from tumors treated with combination therapy of
different nanoparticles (Figure 6b). EGFR targeted gel-
atin nanoparticles treated tumors show moderately in-
creased caspase 3 and significantly increased PARP
levels compared to those treated with SH-Gel and SH-n nanoparticles. (a) Volume change as a function of time showing
el, Gem-Gel-PEG and Gem-Gel-PEG-peptide nanoparticle treated tumor
nted as mean ± SD (n = 6; *p < 0.05; **p < 0.01; ***p < 0.001).
Figure 4 Assessment of apoptosis mediated cell death induction by gemcitabine conjugated gelatin nanoparticles. (a) mRNA expression
profile for transcription factors in the apoptotic pathway (n = 6, *p < 0.05; **p < 0.01; ***p < 0.001). (b) Western blot analysis for cleaved PARP,
cleaved caspase 3 and β-actin protein expression in treated tumors. (c) TUNEL stained images of treated tumors indicating DNA fragmentation
(brown stain). All images were acquired at 20× with scale bar of 50 μm.
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tumor also confirmed that EGFR-targeted nanoparticle
treated tumor section show highest population of cells
undergoing apoptosis (brown TUNEL positive cells)
compared to those treated with SH-Gel and SH-Gel-PEG
(Figure 6c). These observations clearly indicated that
treatment with wt-p53, followed by gemcitabine has
triggered the apoptotic pathway to a higher extent in tu-
mors through up-regulation of pro-apoptotic transfectionFigure 5 In vivo efficacy assessment of wt-p53/gemcitabine combinat
57.6***, 63.3.7*** and 77.3%*** reduction in tumor growth on day 33 for SH
respectively. (b) Tumor weights measured at day 33. Results are presentedfactors and down-regulation of anti-apoptotic transfec-
tion factors.
Discussion
Chemotherapy alone does not show significant improve-
ment in prognosis of pancreatic cancer and novel com-
bination therapies are therefore actively pursued to
achieve synergistic therapeutic benefits. Gene therapy in-
volving p53 gene replacement in combination with aion treatment. (a) Volume change as a function of time showing
-Gel, SH-Gel-PEG and SH-Gel-PEG-peptide nanoparticle treated tumor
as mean ± SD (n = 6; ***p < 0.001).
Figure 6 Transfection and apoptosis induction efficiency of combination treatment. (a) mRNA expression profile for p53 and transcription
factors in the apoptotic pathway. (n = 6, *p < 0.05; **p < 0.01; ***p < 0.001). (b) Western blot analysis for cleaved PARP, cleaved caspase 3 and
β-actin protein expression in treated tumors. (c) TUNEL stained images of treated tumors indicating DNA fragmentation (brown stain). All images
were acquired at 20× with scale bar of 50 μm.
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http://www.biomedcentral.com/1471-2407/14/75genotoxic drug such as gemcitabine is a promising direc-
tion since the drug induces DNA damage [37] while p53
plays a key role in cellular response to such damage [15].
Delivery of a gene or drug to its site of action in vivo how-
ever is an extremely challenging task due to presence of
several physico-chemical and physiological barriers. For-
mulation of a therapeutic moiety in a delivery vector is
therefore of utmost importance to prevent drug/gene deg-
radation or rapid clearance by the reticulo-endothelial sys-
tem (RES) and provide a favorable pharmacokinetic
profile. The surface of the delivery vehicle could be also
leveraged to design a site-specific receptor targeted system
to improve tumor accumulation ability thereby enhancing
the therapeutic benefit of the payload.
We have developed a long-circulating thiolated gelatin-
based redox responsive system that delivers the payload in
response to the intracellular glutathione-mediated reducing
environment [25]. We have previously demonstrated its
successful application in gene delivery in vitro [20,26] as
well as favorable systemic biodistribution in vivo [24,27].
Recently, we have successfully formulated a gelatin
nanoparticle-based system for delivery of gemcitabine, the
frontline drug used in treatment of pancreatic cancer. In
the present work, we study the efficacy effect of gelatin
loaded with wt-p53 gene and gemcitabine independently as
well as in combination in subcutaneous human pancreatic
adenocarcinoma (Panc-1) bearing female SCID beige mice.
One of the main aims of this work was to study the
therapeutic benefit from targeting the nano-deliverysystem in vivo. We designed 3 thiolated gelatin nanopar-
ticle systems, SH-Gel, SH-Gel-PEG and EGFR-targeted
SH-Gel-PEG-peptide that were either loaded with wt-
p53 gene or gemcitabine. Biodistribution studies with
these particles have previously revealed that mean resi-
dence time (MRT) of these particles is significantly
higher and that addition of PEG corona did not neces-
sarily increase it further. Presence of EGFR-targeting
peptide on the surface however did result in a higher
nanoparticle accumulation in the tumor indicating po-
tential therapeutic advantage [27]. Targeted nanoparticle
system was therefore tested against parent therapeutic
component as well as non-targeted and non-PEG coated
nanoparticles to confirm the indication from biodistribu-
tion profile. Another important aim of the study was to
investigate the efficacy result of individual gene or drug
treatment and compare it with therapeutic outcome of
gene/drug combination treatment.
Therapeutic efficacy of targeted nanoparticles were
compared to the non-targeted and non-PEG modified gel-
atin nanoparticles for wt-p53 treatment alone, gemcitabine
treatment alone and the combination treatment and the
targeted particles outperformed all the other treatment
groups in the respective therapeutic regimen. They
showed much higher tumor growth inhibition capability
resulting in lowest tumor weight for each category of
treatment regimen, confirming that active targeting of the
tumor in vivo has promising therapeutic potential. Both
p53 and gemcitabine show tumor growth suppression
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http://www.biomedcentral.com/1471-2407/14/75activity owing to their induction and regulation of apop-
tosis and thus we checked the mRNA levels of the pro
and anti-apoptotic transcription factor as well as down-
stream apoptotic protein expression in the treated tumors.
All the therapeutic procedures adopted in the study
consistently showed an increased upregulation of pro-
apoptotic transcription factors and apoptotic protein
marker in tumors treated with targeted system compared
to control and other gelatin nanoparticle-based formula-
tion. TUNEL staining of the tumor sections gave a visual
evidence of increased apoptotic cells consistent with the
trends observed by mRNA and protein levels assessment.
All these results clearly indicate that targeting strategy is
important to enhance the drug delivery efficiency of the
nano-systems and should be actively pursued to improve
the performance of the formulation.
Cytotoxic drug administration in combination with gene
therapy is a promising approach for the treatment of pan-
creatic cancer especially since drugs alone have failed to
give a promising outcome in disease prognosis. Our results
conclusively demonstrate improved therapeutic efficacy
when wt-p53 gene is administered into the tumor bearing
mice in combination with gemcitabine. Targeted thiolated
gelatin system presents an improved tumor growth sup-
pression activity in combination therapy (77.3%) compared
to wt-p53 (50.1%) or gemcitabine (61.7%) treatment alone.
Pro-apoptotic transcription factor and apoptotic protein
marker expression is also significantly increased in the
combination treatment and the TUNEL stained tumor sec-
tions show a marked increased in the apoptotic cell popu-
lation. These results cement the hypothesis that otherwise
persistent pancreatic cancer tumors would potentially
show an improved response to a gene/drug combination
therapy, when administered within a delivery vector to ob-
tain a favorable pharmacokinetic profile.
Conclusions
Redox-responsive EGFR-targeted thiolated gelatin-based
delivery system was designed for wt-p53 expressing plas-
mid or gemcitabine encapsulation and subsequent treat-
ment of pancreatic cancer in subcutaneous tumor bearing
SCID mice. Gene/drug combination treatment groups
show significantly greater anti-tumor activity compared to
the gene or drug alone treatments groups and among the
combination treatment groups, targeted nanoparticles ex-
hibit superior efficacy. Molecular level assessment con-
firms that tumor growth inhibition for all the treatment
groups take effect by induction of apoptosis.
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